Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
| Revenue (TTM) | $22.23B |
| Gross Profit (TTM) | $10.47B |
| EBITDA | $6.16B |
| Operating Margin | 14.70% |
| Return on Equity | 6.67% |
| Return on Assets | 4.38% |
| Revenue/Share (TTM) | $77.99 |
| Book Value | $87.58 |
| Price-to-Book | 1.78 |
| Price-to-Sales (TTM) | 2.01 |
| EV/Revenue | 2.679 |
| EV/EBITDA | 11.98 |
| Quarterly Earnings Growth (YoY) | 28.60% |
| Quarterly Revenue Growth (YoY) | 5.20% |
| Shares Outstanding | $275.54M |
| Float | $274.69M |
| % Insiders | 0.42% |
| % Institutions | 99.19% |
Volatility is currently expanding
Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients. FRANKLIN LAKES, N.J.
FRANKLIN LAKES, N.J., July 28, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on September 30, 2026, to holders of record on September 9, 2026.
FRANKLIN LAKES, N.J., July 22, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2.
FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Becton, Dickinson and Company delivered solid Q2 2026 results, with EPS of $2.90 beating estimates by $0.13. Revenue reached $4.7B, exceeding consensus by $30M and marking a 5.2% YoY increase post-spin-off of BD Life Sciences & Diagnostic Solutions. The company boasts a few high-margin, high-growth product lines that should fuel a return to sustainable growth.
Becton, Dickinson and Company is undervalued, trading at 12–13x P/E despite forecasted 7%–8% annual growth and improving fundamentals. BDX's sector-wide pressures are driven by cautious hospital spending, higher rates, and capital rotation into AI, but its core operations remain robust. BDX maintains a BBB rating, conservative leverage, a 2.78% dividend with 44+ years of increases, and is executing $2B in buybacks while retiring $2.1B in debt.
Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety FRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company.
Despite facing some headwinds, these three companies still have strong long-term prospects. All three have raised their payouts for more than 50 consecutive years.
Representative Thomas H. Kean Jr, a Republican from New Jersey who sits on the House Energy and Commerce Committee, has disclosed four new congressional stock trades.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BDX and any ticker you trade — then tracks every position and per-strategy win rate.
